• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    First line Immunotherapy for Non-Small Cell Lung Cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Nasser, Nicola J
    Gorenberg, Miguel
    Agbarya, Abed
    Date
    2020-11-08
    Journal
    Pharmaceuticals (Basel, Switzerland)
    Publisher
    MDPI AG
    Type
    Article
    Other
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.3390/ph13110373
    Abstract
    Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first line treatments protocols. Multiple phase 3 studies have tested different medications targeting programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), with or without chemotherapy. The inclusion criteria differ between the various clinical trials, including the cut-off levels of PD-L1 expression on tumor cells, and the tumor histology (squamous or non-squamous). Patients with tumor expression levels of PD-L1 ≥ 50% are candidates for treatment with single agent Pembrolizumab or Atezolizumab. Patients with PD-L1 < 50% are candidates for immunotherapy with pembrolizumab as a single agent if PL-1 > 1%; immunotherapy doublet, Nivolumab and Ipilimumab, or single agent immunotherapy combined with chemotherapy. Here we review phase 3 clinical trials utilizing immunotherapy in the first line for treatment of NSCLC, including Pembrolizumab in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189 and KEYNOTE-407; Nivolumab and Ipilimumab in CHECKMATE-227 and CHECKMATE 9LA; and Atezolizumab in IMpower110, IMpower130 and IMpower150.
    Keyword
    CTLA-4
    chemotherapy
    immune checkpoints inhibitors
    lung cancer
    monoclonal recombinant antibodies
    programmed death receptor
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/14179
    ae974a485f413a2113503eed53cd6c53
    10.3390/ph13110373
    Scopus Count
    Collections
    UMB Open Access Articles

    entitlement

    Related articles

    • Nivolumab plus ipilimumab in non-small-cell lung cancer.
    • Authors: Reck M, Borghaei H, O'Byrne KJ
    • Issue date: 2019 Jul
    • A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression.
    • Authors: Herbst R, Jassem J, Abogunrin S, James D, McCool R, Belleli R, Giaccone G, De Marinis F
    • Issue date: 2021
    • Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    • Authors: Zhang Y, Zhou H, Zhang L
    • Issue date: 2018 Dec 3
    • The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    • Authors: Mahoney KM, Freeman GJ, McDermott DF
    • Issue date: 2015 Apr 1
    • A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.
    • Authors: Halmos B, Burke T, Kalyvas C, Insinga R, Vandormael K, Frederickson A, Piperdi B
    • Issue date: 2020 Dec 4
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.